PT  - JOURNAL ARTICLE
AU  - Yuesong Pan
AU  - Xia Meng
AU  - Weiqi Chen
AU  - Jing Jing
AU  - Jinxi Lin
AU  - Yong Jiang
AU  - S Claiborne Johnston
AU  - Philip M Bath
AU  - Qiang Dong
AU  - An-Ding Xu
AU  - Hao Li
AU  - Yongjun Wang
TI  - Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial
AID  - 10.1136/svn-2021-001480
DP  - 2022 Oct 01
TA  - Stroke and Vascular Neurology
PG  - e001480
VI  - 7
IP  - 5
4099  - http://svn.bmj.com/content/7/5/e001480.short
4100  - http://svn.bmj.com/content/7/5/e001480.full
SO  - Stroke Vasc Neurol2022 Oct 01; 7
AB  - Background Indobufen can reversibly inhibit platelet aggregation and showed to be effective in the treatment of ischaemic heart and peripheral vascular diseases. However, it is unclear whether indobufen is an alternative antiplatelet agent for treatment of patients with ischaemic stroke.Aim To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke.Design The Indobufen vs Aspirin in Acute Ischaemic Stroke (INSURE) is a randomised, double-blind, double-dummy, positive drug control, non-inferior multicentre clinical trial conducted in 200 hospitals in China. Participants will be randomised at a 1:1 ratio to receive either 100 mg indofufen two times daily or 100 mg aspirin once daily within 72 hours of the onset of symptoms from day 1 to 3 months.Study outcomes The primary efficacy outcome is a new stroke (ischaemic or haemorrhagic) within 3 months and the primary safety outcome is a severe or moderate bleeding event within 3 months.Discussion The INSURE trial will evaluate whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke.Trial registration number NCT03871517.No data are available. Not applicable.